ReviewAdvances in therapy2025
Metformin: Old Drug, New Therapeutic Potential in the Skin? A Brief Narrative Review.
Review in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- [Q-switched Nd:YAG 1064 nm laser combined with topical metformin lotion for treatment of chloasma in mice].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Metformin as an Adjunct in Periodontal Therapy: Mechanistic Insights, Research Evidence and Current Challenges.Therapeutic innovation & regulatory science · 2026Review
- Neurohormonal-Immune Dysregulation in Rosacea: Emerging Perspectives from the Skin-Gut-Brain Axis.Drug design, development and therapy · 2026Review
- Metformin as a potential adjunct in the treatment of mild-to-moderate ulcerative colitis: a double-blind, randomized, placebo-controlled pilot study.Internal and emergency medicine · 2025Article
- Senotherapeutic Potential of Araliadiol in Senescent Human Dermal Fibroblasts: An In Vitro Study Using Three Senescence Models.Pharmaceutics · 2025Article
- Novel insights into the hepatoprotective mechanisms of SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin, a well-established, first-line therapy for type 2 diabetes mellitus, is still gaining interest for its potential applications beyond glycaemic control. In addition to its insulin-sensitising effects, metformin exhibits anti-inflammatory, antioxidant, anti-proliferative, and immunomodulatory properties, rendering it a promising candidate for various dermatological conditions. Emerging evidence suggests that metformin may play a beneficial role in inflammatory skin diseases, such as acne, hidradenitis suppurativa, acanthosis nigricans, rosacea and psoriasis. Furthermore, recent studies highlight its potential in promoting wound healing and modulating skin ageing. This narrative review summarises current knowledge of the mechanisms of action of metformin in dermatology and explores its potential as a novel therapeutic approach for skin disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.